Clinical Trials
162 trialsROXI-CAT-I
Regeneron Pharmaceuticals
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
LIBERTY
Swedish Orphan Biovitrum
MAGNOLIA
Anthos Therapeutics, Inc.
FRIENDS-01
The First Affiliated Hospital with Nanjing Medical University
ROXI-CAT-II
Regeneron Pharmaceuticals
AVAJAK
University Hospital, Brest
ASTER
Anthos Therapeutics, Inc.
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
DOAC
University of Vermont
CATIQ P3
Quercis Pharma AG
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
Kexing Biopharm Co., Ltd.
MATCH
University of Texas Southwestern Medical Center
MYELAXAT
University Hospital, Grenoble
PTCA199-3
Fudan University
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
INDEPENDENCE
Celgene
TRIM-Line
Ottawa Hospital Research Institute
CARAVAGGIO
Fadoi Foundation, Italy
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Jiangsu HengRui Medicine Co., Ltd.
FORGE II
AHS Cancer Control Alberta
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
LEO Pharma
TRANSPORT
Assistance Publique - Hôpitaux de Paris
AMADEUS
University of Birmingham
1703/1801
Medical College of Wisconsin
Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)
Ontario Clinical Oncology Group (OCOG)
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
National Cancer Institute (NCI)
END
Brigham and Women's Hospital
Romiplostim in Chemotherapy-Induced Thrombocytopenia
Ain Shams University
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Sobi, Inc.
A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
APEX
Alexion Pharmaceuticals, Inc.
GBT_HOPE
Pfizer
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Eastern Cooperative Oncology Group
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Eastern Cooperative Oncology Group
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Kyntra Bio
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Blau Farmaceutica S.A.
HAVEN 4
Hoffmann-La Roche
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen
PROVE
Assistance Publique - Hôpitaux de Paris
HAVEN 3
Hoffmann-La Roche
FORGE
Alberta Health Services, Calgary
PRO-LAPSII
Fadoi Foundation, Italy
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.